Company Analysis
Sign in

Stoke Therapeutics, Inc. (STOK)

Nasdaq: STOK · Pharmaceutical Preparations · Bedford, MA · filing with the SEC since 2014
Full chart Alerts Compare
Grade6.3
◀ Past 5.4● Present 6.9▶ Future 6.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Stoke Therapeutics, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 1 in 2023
Applications published
25
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Stoke Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
25 published
STOKE THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
8 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 24, 202512,338,437OPA1 antisense oligomers for treatment of conditions and diseasesPharmaceuticalsSTOKE THERAPEUTICS, INC.
Aug 13, 202412,060,558Methods and compositions for treatment of cholesteryl ester storage diseasePharmaceuticalsSTOKE THERAPEUTICS, INC.
Jan 16, 202411,873,490Antisense oligomers for treatment of conditions and diseasesBiotechnologySTOKE THERAPEUTICS, INC.
Nov 14, 202311,814,622OPA1 antisense oligomers for treatment of conditions and diseasesPharmaceuticalsSTOKE THERAPEUTICS, INC.
Aug 24, 202111,096,956Antisense oligomers and uses thereofPharmaceuticalsSTOKE THERAPEUTICS, INC.
Aug 10, 202111,083,745Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet SyndromePharmaceuticalsSTOKE THERAPEUTICS, INC.
Feb 9, 202110,913,947Antisense oligomers for treatment of conditions and diseasesBiotechnologySTOKE THERAPEUTICS, INC.
Jun 16, 202010,683,503Antisense oligomers for treatment of conditions and diseasesBiotechnologySTOKE THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388902ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASESBiotechnologyStoke Therapeutics, Inc.
Jul 31, 20252025/0243493COMPOUNDS FOR TREATMENT OF CONDITIONS AND DISEASESPharmaceuticalsStoke Therapeutics, Inc.
Feb 27, 20252025/0066781METHODS FOR TREATING CONDITIONS AND DISEASESBiotechnologyStoke Therapeutics, Inc.
Feb 20, 20252025/0059535OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASESBiotechnologyStoke Therapeutics, Inc.
Aug 1, 20242024/0254488ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASESBiotechnologyStoke Therapeutics, Inc.
May 9, 20242024/0150760ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASESBiotechnologyStoke Therapeutics, Inc.
Apr 11, 20242024/0117353COMPOSITIONS FOR TREATMENT OF CONDITIONS AND DISEASES ASSOCIATED WITH POLYCYSTIN EXPRESSIONBiotechnologyStoke Therapeutics, Inc.
Mar 28, 20242024/0102011OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASESPharmaceuticalsStoke Therapeutics, Inc.
Feb 1, 20242024/0033378ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASESBiotechnologyStoke Therapeutics, Inc.
Sep 14, 20232023/0287410OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASESPharmaceuticalsStoke Therapeutics, Inc. · patent 12,338,437 granted from it
What it applied for, 2024 to 2025: Biotechnology 7 · Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton STOK · research, not advice